← Back to Search

Focused Ultrasound

Transcranial ExAblate for Essential Tremor

N/A
Waitlist Available
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up participants will be followed from the date of treatment until study completion, approximately up to 12 months
Awards & highlights

Summary

This trial is testing a new treatment for essential tremor that is safe and effective.

Eligible Conditions
  • Essential Tremor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants will be followed from the date of treatment until study completion, approximately up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and participants will be followed from the date of treatment until study completion, approximately up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The incidence and severity of adverse events (AEs)
Secondary outcome measures
Effectiveness of the ExAblate Transcranial MRgFUS treatment of medication-refractory Essential Tremor (ET) will be determined using the Clinical Rating Scale for Tremor (CRST)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Transcranial ExAblateExperimental Treatment1 Intervention
Transcranial ExAblate
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial ExAblate
2013
N/A
~80

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
89 Previous Clinical Trials
3,664 Total Patients Enrolled
12 Trials studying Essential Tremor
1,018 Patients Enrolled for Essential Tremor
~5 spots leftby Jul 2025